HRP20221211T1 - Car-izražavajući vektor i t-stanice koje izražavaju car - Google Patents
Car-izražavajući vektor i t-stanice koje izražavaju car Download PDFInfo
- Publication number
- HRP20221211T1 HRP20221211T1 HRP20221211TT HRP20221211T HRP20221211T1 HR P20221211 T1 HRP20221211 T1 HR P20221211T1 HR P20221211T T HRP20221211T T HR P20221211TT HR P20221211 T HRP20221211 T HR P20221211T HR P20221211 T1 HRP20221211 T1 HR P20221211T1
- Authority
- HR
- Croatia
- Prior art keywords
- nucleic acid
- acid encoding
- car
- preparing
- interleukin
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims 17
- 239000013604 expression vector Substances 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 claims 26
- 108020004707 nucleic acids Proteins 0.000 claims 26
- 150000007523 nucleic acids Chemical class 0.000 claims 26
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 16
- 102000000704 Interleukin-7 Human genes 0.000 claims 9
- 108010002586 Interleukin-7 Proteins 0.000 claims 9
- -1 c-Met Proteins 0.000 claims 9
- 229940100994 interleukin-7 Drugs 0.000 claims 9
- 102100036842 C-C motif chemokine 19 Human genes 0.000 claims 8
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 claims 8
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 6
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 6
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 6
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 6
- 239000013598 vector Substances 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 3
- 101001005269 Arabidopsis thaliana Ceramide synthase 1 LOH3 Proteins 0.000 claims 3
- 101001005312 Arabidopsis thaliana Ceramide synthase LOH1 Proteins 0.000 claims 3
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 3
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 3
- 102100032912 CD44 antigen Human genes 0.000 claims 3
- 102100028801 Calsyntenin-1 Human genes 0.000 claims 3
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 3
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 3
- 102000010451 Folate receptor alpha Human genes 0.000 claims 3
- 108050001931 Folate receptor alpha Proteins 0.000 claims 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 3
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 3
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 3
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 3
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 3
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 3
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 3
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 claims 3
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 3
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 3
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 3
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 3
- 101001051490 Homo sapiens Neural cell adhesion molecule L1 Proteins 0.000 claims 3
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 3
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 3
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims 3
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 3
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 3
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 3
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims 3
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 3
- 102000003735 Mesothelin Human genes 0.000 claims 3
- 108090000015 Mesothelin Proteins 0.000 claims 3
- 102100034256 Mucin-1 Human genes 0.000 claims 3
- 102100023123 Mucin-16 Human genes 0.000 claims 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 3
- 102000003729 Neprilysin Human genes 0.000 claims 3
- 108090000028 Neprilysin Proteins 0.000 claims 3
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims 3
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 3
- 102100040120 Prominin-1 Human genes 0.000 claims 3
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 3
- 101000668858 Spinacia oleracea 30S ribosomal protein S1, chloroplastic Proteins 0.000 claims 3
- 101000898746 Streptomyces clavuligerus Clavaminate synthase 1 Proteins 0.000 claims 3
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims 3
- 230000003834 intracellular effect Effects 0.000 claims 3
- HUOOMAOYXQFIDQ-UHFFFAOYSA-N isoginkgetin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C(C=3C(=CC=C(C=3)C=3OC4=CC(O)=CC(O)=C4C(=O)C=3)OC)=C2O1 HUOOMAOYXQFIDQ-UHFFFAOYSA-N 0.000 claims 3
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 3
- 230000036737 immune function Effects 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464424—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464436—Cytokines
- A61K39/46444—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464436—Cytokines
- A61K39/464442—Chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5418—IL-7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (11)
1. Metoda za pripremu T-stanice koja izražava himerni antigenski receptor (CAR), interleukin-7 i CCL19, koja uključuje uvođenje nukleinske kiseline koja kodira CAR i nukleinske kiseline koja kodira čimbenik za poboljšanje imunološke funkcije T-stanica pomoću jednog ili više vektora u T-stanicu, u kojoj nukleinska kiselina koja kodira faktor imunološke funkcije T-stanice sadrži nukleinsku kiselinu koja kodira interleukin-7 i nukleinsku kiselinu koja kodira CCL19.
2. Metoda za pripremu T-stanice prema patentnom zahtjevu 1, koja se sastoji od uvođenja vektora u T-stanicu koji sadrži nukleinsku kiselinu koja kodira CAR, nukleinsku kiselinu koja kodira interleukin-7 i nukleinsku kiselinu koja kodira CCL19.
3. Metoda za pripremu T-stanice prema patentnom zahtjevu 2, pri čemu su nukleinska kiselina koja kodira CAR i nukleinska kiselina koji kodira interleukin-7, te nukleinska kiselina koja kodira interleukin-7 i nukleinska kiselina koja kodira CCL19, povezane preko nukleinske kiseline koja kodira samocijepajući peptid.
4. Metoda za pripremu T-stanice prema patentnom zahtjevu 1, koja se sastoji od uvođenja vektora u T-stanicu koji sadrži nukleinsku kiselinu koja kodira CAR i nukleinsku kiselinu koja kodira interleukin-7, i vektora koji sadrži nukleinsku kiselinu koja kodira CAR i nukleinsku kiselinu koja kodira CCL19.
5. Metoda za pripremu T-stanice prema patentnom zahtjevu 4, pri čemu su nukleinska kiselina koja kodira CAR i nukleinska kiselina koja kodira interleukin-7, te nukleinska kiselina koja kodira CAR i nukleinska kiselina koja kodira CCL19, redom, povezane preko nukleinske kiseline koja kodira samocijepajući peptid.
6. Metoda za pripremu T-stanice prema bilo kojem prethodnom patentnom zahtjevu, pri čemu CAR sadrži jednolančano protutijelo koje prepoznaje antigen odabran iz skupine koju čine CD20, EGFR, FITC, CD19, CD22, CD33, PSMA, GD2, EGFR varijanta, ROR1, c-Met, HER2, CEA, mezotelin, GM2, CD7, CD10, CD30, CD34, CD38, CD41, CD44, CD74, CD123 CD133, CD171, MUC16, MUC1, CS1(CD319), IL-13Ra2, BCMA, Lewis Y, IgG kappa lanac, folatni receptor-alfa, PSCA i EpCAM.
7. Metoda za pripremu T-stanice prema bilo kojem prethodnom patentnom zahtjevu, pri čemu nukleinska kiselina koja kodira CAR sadrži nukleinsku kiselinu koja kodira polipeptid CD8 transmembranske regije.
8. Metoda za pripremu T-stanice prema bilo kojem prethodnom patentnom zahtjevu, pri čemu nukleinska kiselina koja kodira CAR sadrži nukleinske kiseline koje kodiraju polipeptide unutarstanične regije CD28, unutarstanične regije 4-1BB i unutarstanične regije CD3ζ.
9. Metoda za pripremu T-stanice prema bilo kojem od patentnih zahtjeva 2 do 8, pri čemu je vektor retrovirusni vektor.
10. Sredstvo protiv raka koje sadrži T-stanicu koja izražava CAR, interleukin-7 i CCL19 i farmaceutski prihvatljiv aditiv, pri čemu CAR sadrži jednolančano protutijelo koje prepoznaje antigen odabran iz skupine koju čine CD20, EGFR, FITC, CD19, CD22, CD33, PSMA, GD2, EGFR varijanta, ROR1, c-Met, HER2, CEA, mezotelin, GM2, CD7, CD10, CD30, CD34, CD38, CD41, CD44, CD74, CD123, CD133, CD171, MUC16, MUC1, CS1(CD319), IL-13Ra2, BCMA, Lewis Y, IgG kappa lanac, folni receptor-alfa, PSCA i EpCAM.
11. T-stanica koja izražava CAR, interleukin-7 i CCL19, pri čemu CAR sadrži jednolančano protutijelo koje prepoznaje antigen odabran iz skupine koju čine CD20, EGFR, FITC, CD19, CD22, CD33, PSMA, GD2, EGFR varijanta, ROR1, c-Met, HER2, CEA, mezotelin, GM2, CD7, CD10, CD30, CD34, CD38, CD41, CD44, CD74, CD123 CD133, CD171, MUC16, MUC1, CS1(CD319), IL-13Ra2, BCMA, Lewis Y, IgG kappa lanac, folni receptor-alfa, PSCA i EpCAM.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014208200 | 2014-10-09 | ||
EP19196196.0A EP3597742B1 (en) | 2014-10-09 | 2015-10-06 | Car expression vector and car-expressing t cells |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20221211T1 true HRP20221211T1 (hr) | 2022-12-09 |
Family
ID=55652864
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20221211TT HRP20221211T1 (hr) | 2014-10-09 | 2015-10-06 | Car-izražavajući vektor i t-stanice koje izražavaju car |
HRP20191839TT HRP20191839T1 (hr) | 2014-10-09 | 2019-10-11 | Car ekspresijski vektor i t stanice koje eksprimiraju car |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20191839TT HRP20191839T1 (hr) | 2014-10-09 | 2019-10-11 | Car ekspresijski vektor i t stanice koje eksprimiraju car |
Country Status (28)
Country | Link |
---|---|
US (3) | US10316102B2 (hr) |
EP (2) | EP3205720B1 (hr) |
JP (5) | JP6161098B2 (hr) |
KR (1) | KR101890638B1 (hr) |
CN (1) | CN107109421B (hr) |
AU (1) | AU2015329444B2 (hr) |
BR (1) | BR112017006710B1 (hr) |
CA (1) | CA2962375C (hr) |
CY (1) | CY1122324T1 (hr) |
DK (2) | DK3205720T3 (hr) |
ES (2) | ES2751945T3 (hr) |
HR (2) | HRP20221211T1 (hr) |
HU (2) | HUE060047T2 (hr) |
IL (1) | IL251504B (hr) |
LT (2) | LT3597742T (hr) |
MX (1) | MX358472B (hr) |
MY (1) | MY167722A (hr) |
NZ (1) | NZ730382A (hr) |
PH (1) | PH12017500596A1 (hr) |
PL (2) | PL3205720T3 (hr) |
PT (2) | PT3205720T (hr) |
RS (2) | RS59441B1 (hr) |
RU (1) | RU2670147C1 (hr) |
SG (1) | SG11201702391RA (hr) |
SI (2) | SI3597742T1 (hr) |
TW (1) | TWI688651B (hr) |
WO (1) | WO2016056228A1 (hr) |
ZA (1) | ZA201701968B (hr) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3597742T (lt) * | 2014-10-09 | 2022-09-12 | Yamaguchi University | Car raiškos vektorius ir t ląstelės, vykdančios car raišką |
GB201509413D0 (en) * | 2015-06-01 | 2015-07-15 | Ucl Business Plc | Fusion protein |
AU2017219859A1 (en) | 2016-02-16 | 2018-08-09 | Dana-Farber Cancer Institute, Inc. | Immunotherapy compositions and methods |
CA3017442A1 (en) * | 2016-03-17 | 2017-09-21 | Yamaguchi University | Immunocompetent cell and expression vector expressing regulatory factors of immune function |
WO2018119518A1 (en) * | 2017-01-01 | 2018-07-05 | Lee Chi Yu Gregory | Rp215 chimeric antigen receptor construct and methods of making and using same |
AU2018208191B2 (en) | 2017-01-10 | 2024-09-12 | National Cancer Center | Anti-GPC3 antibody |
MX2019011404A (es) * | 2017-03-27 | 2020-02-05 | Noile Immune Biotech Inc | Receptor de antigeno quimerico. |
CN108484777B (zh) * | 2017-03-31 | 2022-07-12 | 李吉祐 | 人源化rp215单克隆抗体的嵌合抗原受体构建体及核酸分子与应用 |
KR20200068661A (ko) * | 2017-10-10 | 2020-06-15 | 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 | 메모리 기능을 갖는 t세포 또는 b세포의 증강제, 악성 종양 재발 억제제 및 t세포 또는 b세포에 메모리 기능을 유도하는 유도제 |
EP3730612A4 (en) * | 2017-12-24 | 2021-09-01 | Noile-Immune Biotech, Inc. | IMMUNOCOMPETENT CELL EXPRESSING A CELL SURFACE MOLECULE SPECIFICALLY RECOGNIZING HUMAN MESOTHELIN, IL-7 AND CCL19 |
MX2020006843A (es) * | 2017-12-27 | 2020-09-03 | Takeda Pharmaceuticals Co | Nanoparticula de lipido que contiene acido nucleico y uso de la misma. |
CN108659133A (zh) * | 2018-04-26 | 2018-10-16 | 上海怡豪生物科技有限公司 | 肺癌的双靶点car-t治疗载体及其构建方法和应用 |
CN108641000A (zh) * | 2018-04-26 | 2018-10-12 | 上海怡豪生物科技有限公司 | 肝癌的双靶点car-t治疗载体及其构建方法和应用 |
CN108641001A (zh) * | 2018-04-26 | 2018-10-12 | 上海怡豪生物科技有限公司 | 结肠癌的双靶点car-t治疗载体及其构建方法和应用 |
WO2019219029A1 (zh) * | 2018-05-15 | 2019-11-21 | 科济生物医药(上海)有限公司 | 基因工程化的细胞及应用 |
KR20190141511A (ko) * | 2018-06-14 | 2019-12-24 | 주식회사 녹십자랩셀 | 신규 펩티드, 이를 포함하는 키메라 항원 수용체 및 이를 발현하는 면역 세포 |
CN108866004A (zh) * | 2018-06-26 | 2018-11-23 | 奥妙生物技术(广州)有限公司 | Shp-1敲除的t细胞及其构建方法 |
JPWO2020017479A1 (ja) * | 2018-07-17 | 2021-08-02 | ノイルイミューン・バイオテック株式会社 | 抗gpc3一本鎖抗体を含むcar |
CN109055430A (zh) * | 2018-08-14 | 2018-12-21 | 杭州荣泽生物科技有限公司 | 一种共表达il18和ccl19蛋白及靶向muc1基因car-t细胞的制备方法 |
EA202190624A1 (ru) | 2018-08-31 | 2021-06-09 | Нойл-Иммьюн Байотек, Инк. | Car-экспрессирующие т-клетки и car-экспрессирующий вектор |
CN112771167A (zh) * | 2018-09-20 | 2021-05-07 | 科济生物医药(上海)有限公司 | 表达有趋化因子的细胞及用途 |
EP3864142A4 (en) * | 2018-10-12 | 2023-07-19 | iCell Gene Therapeutics LLC | CHIMERIC ANTIGEN RECEPTOR (CARS) COMPOSITIONS AND METHODS OF USE THEREOF |
CN109504660B (zh) * | 2018-11-02 | 2021-08-06 | 温州启星生物技术有限公司 | 一种第四代car-t细胞及其构建方法和应用 |
WO2020106621A1 (en) * | 2018-11-19 | 2020-05-28 | Board Of Regents, The University Of Texas System | A modular, polycistronic vector for car and tcr transduction |
EP3934666A1 (en) * | 2019-03-08 | 2022-01-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
CN112080525A (zh) * | 2019-06-14 | 2020-12-15 | 南京艾德免疫治疗研究院有限公司 | 一种改良型嵌合抗原受体t细胞的制备 |
CN112080526A (zh) * | 2019-06-14 | 2020-12-15 | 南京艾德免疫治疗研究院有限公司 | 表达il-7和car的表达载体及免疫细胞 |
JP2021016371A (ja) * | 2019-07-23 | 2021-02-15 | 株式会社東芝 | Car−t細胞の製造方法、核酸導入キャリア及びキット |
WO2021085497A1 (ja) | 2019-10-28 | 2021-05-06 | ノイルイミューン・バイオテック株式会社 | がんを治療するための医薬、組み合わせ医薬、医薬組成物、免疫応答性細胞、核酸送達媒体、及び製品 |
CN110922490B (zh) * | 2019-12-05 | 2023-03-03 | 浙江启新生物技术有限公司 | 分泌白介素7和趋化因子21的car表达载体及应用 |
JP2023513752A (ja) * | 2020-02-14 | 2023-04-03 | ベイジン ヨンタイ ルイケ バイオテクノロジー カンパニー リミテッド | 外部から導入された細胞シグナル伝達調節因子を過剰発現する免疫細胞及びその使用 |
WO2021213479A1 (zh) * | 2020-04-22 | 2021-10-28 | 复星凯特生物科技有限公司 | Shp2特异性失活突变蛋白及其在car-t治疗中应用 |
GB202006820D0 (en) * | 2020-05-07 | 2020-06-24 | Autolus Ltd | Cell |
CN115885038A (zh) | 2020-06-17 | 2023-03-31 | 国立大学法人京都大学 | 表达嵌合抗原受体的免疫活性细胞 |
KR102297396B1 (ko) | 2020-07-29 | 2021-09-06 | (주)티카로스 | 면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포 |
JP2023553157A (ja) | 2020-12-10 | 2023-12-20 | ユーティレックス カンパニー リミテッド | 抗-pd-1抗体およびその用途 |
WO2022135357A1 (en) * | 2020-12-22 | 2022-06-30 | Sunshine Lake Pharma Co., Ltd. | A hIL7/hCCL19 DOUBLE GENE RECOMBINANT ONCOLYTIC VIRUS AND ITS PREPARATION METHOD AND USE |
CN114716548A (zh) | 2021-01-05 | 2022-07-08 | (株)爱恩德生物 | 抗-fgfr3抗体及其用途 |
CN112961248B (zh) * | 2021-02-22 | 2022-03-18 | 广州百暨基因科技有限公司 | 共表达IL-7和CCR2b的嵌合抗原受体融合蛋白及其应用 |
WO2022245098A1 (ko) | 2021-05-18 | 2022-11-24 | 주식회사 바이오솔루션 | 세포외소포체 분비능이 증진된 면역세포 및 이를 활용한 면역 항암요법 |
CA3227581A1 (en) * | 2021-07-29 | 2023-02-02 | Takeda Pharmaceutical Company Limited | Engineered immune cell that specifically targets mesothelin and uses thereof |
CN113913385A (zh) * | 2021-09-01 | 2022-01-11 | 苏州璞惠卓越生物科技有限公司 | 一种抑制蛋白阻断型嵌合抗原受体修饰的免疫细胞及其用途 |
CN113921082B (zh) * | 2021-10-27 | 2023-04-07 | 云舟生物科技(广州)股份有限公司 | 基因搜索权重调整方法、计算机存储介质及电子设备 |
WO2023081455A2 (en) * | 2021-11-08 | 2023-05-11 | Memorial Sloan-Kettering Cancer Center | Immune cells expressing glucose transporter 5 (gluts) and compositions and methods including the same |
WO2023223292A1 (en) * | 2022-05-20 | 2023-11-23 | Takeda Pharmaceutical Company Limited | Methods of producing engineered immune cells |
US12006353B2 (en) | 2022-07-25 | 2024-06-11 | Long Chen | Application of SCFV protein, car gene expression vector, CAR-T cell and application thereof |
CN115505601B (zh) * | 2022-10-17 | 2024-05-28 | 深圳市先康达生命科学有限公司 | 一种两级SynNotch逻辑调控结构及其应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5857318A (ja) * | 1981-10-01 | 1983-04-05 | Nippon Koutai Kenkyusho:Kk | 癌細胞障害性リンパ球の製造法 |
EP1334188B1 (en) | 2000-11-07 | 2006-08-30 | City of Hope | Cd19-specific redirected immune cells |
KR20050118057A (ko) * | 2004-04-24 | 2005-12-15 | 김상희 | 아세틸디아실글리세롤류의 화합물을 유효성분으로함유하는 항암제 및 건강식품 |
TWI436775B (zh) * | 2007-08-24 | 2014-05-11 | Oncotherapy Science Inc | 以抗原胜肽合併化療藥劑治療胰臟癌 |
BRPI0920679A2 (pt) | 2008-10-08 | 2022-05-17 | Intrexon Corp | Células construídas expressando múltiplos imunomoduladores e usos das mesmas |
PT3214091T (pt) | 2010-12-09 | 2019-01-11 | Univ Pennsylvania | Utilização de células t modificadas por recetor de antigénio quimérico para tratar o cancro |
CA3102782A1 (en) * | 2010-12-14 | 2012-06-21 | University Of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
AU2012240562B2 (en) | 2011-04-08 | 2016-12-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer |
US20130071414A1 (en) * | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
WO2013040371A2 (en) * | 2011-09-16 | 2013-03-21 | Baylor College Of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
KR101956751B1 (ko) | 2011-10-07 | 2019-03-11 | 고쿠리츠다이가쿠호진 미에다이가쿠 | 키메라 항원 수용체 |
EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
KR20140127829A (ko) * | 2012-02-22 | 2014-11-04 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 2세대 키메라 항원 수용체에서 cd2 시그널링 도메인의 용도 |
CN102625373A (zh) * | 2012-02-22 | 2012-08-01 | 中兴通讯股份有限公司 | 一种智能载波管理方法及装置 |
LT3597742T (lt) * | 2014-10-09 | 2022-09-12 | Yamaguchi University | Car raiškos vektorius ir t ląstelės, vykdančios car raišką |
-
2015
- 2015-10-06 LT LTEP19196196.0T patent/LT3597742T/lt unknown
- 2015-10-06 PL PL15849416T patent/PL3205720T3/pl unknown
- 2015-10-06 HR HRP20221211TT patent/HRP20221211T1/hr unknown
- 2015-10-06 NZ NZ730382A patent/NZ730382A/en unknown
- 2015-10-06 SI SI201531887T patent/SI3597742T1/sl unknown
- 2015-10-06 MX MX2017004393A patent/MX358472B/es active IP Right Grant
- 2015-10-06 CN CN201580053922.1A patent/CN107109421B/zh active Active
- 2015-10-06 RS RSP20191315 patent/RS59441B1/sr unknown
- 2015-10-06 BR BR112017006710A patent/BR112017006710B1/pt active IP Right Grant
- 2015-10-06 PL PL19196196.0T patent/PL3597742T3/pl unknown
- 2015-10-06 WO PCT/JP2015/005080 patent/WO2016056228A1/ja active Application Filing
- 2015-10-06 EP EP15849416.1A patent/EP3205720B1/en active Active
- 2015-10-06 ES ES15849416T patent/ES2751945T3/es active Active
- 2015-10-06 US US15/513,870 patent/US10316102B2/en active Active
- 2015-10-06 RU RU2017114545A patent/RU2670147C1/ru active
- 2015-10-06 HU HUE19196196A patent/HUE060047T2/hu unknown
- 2015-10-06 JP JP2016552830A patent/JP6161098B2/ja active Active
- 2015-10-06 AU AU2015329444A patent/AU2015329444B2/en active Active
- 2015-10-06 CA CA2962375A patent/CA2962375C/en active Active
- 2015-10-06 DK DK15849416.1T patent/DK3205720T3/da active
- 2015-10-06 EP EP19196196.0A patent/EP3597742B1/en active Active
- 2015-10-06 RS RS20220895A patent/RS63601B1/sr unknown
- 2015-10-06 LT LT15849416T patent/LT3205720T/lt unknown
- 2015-10-06 PT PT158494161T patent/PT3205720T/pt unknown
- 2015-10-06 SI SI201530950T patent/SI3205720T1/sl unknown
- 2015-10-06 SG SG11201702391RA patent/SG11201702391RA/en unknown
- 2015-10-06 HU HUE15849416A patent/HUE046710T2/hu unknown
- 2015-10-06 DK DK19196196.0T patent/DK3597742T3/da active
- 2015-10-06 MY MYPI2017701137A patent/MY167722A/en unknown
- 2015-10-06 PT PT191961960T patent/PT3597742T/pt unknown
- 2015-10-06 ES ES19196196T patent/ES2927366T3/es active Active
- 2015-10-06 KR KR1020177009895A patent/KR101890638B1/ko active IP Right Grant
- 2015-10-08 TW TW104133272A patent/TWI688651B/zh active
-
2017
- 2017-03-22 ZA ZA2017/01968A patent/ZA201701968B/en unknown
- 2017-03-31 PH PH12017500596A patent/PH12017500596A1/en unknown
- 2017-04-02 IL IL251504A patent/IL251504B/en active IP Right Grant
- 2017-06-06 JP JP2017111736A patent/JP6683990B2/ja active Active
-
2019
- 2019-05-06 US US16/404,165 patent/US10906984B2/en active Active
- 2019-10-11 HR HRP20191839TT patent/HRP20191839T1/hr unknown
- 2019-11-26 CY CY20191101239T patent/CY1122324T1/el unknown
-
2020
- 2020-03-19 JP JP2020048623A patent/JP7008350B2/ja active Active
- 2020-12-23 US US17/133,286 patent/US20210253726A1/en active Pending
-
2021
- 2021-12-28 JP JP2021213604A patent/JP7300763B2/ja active Active
-
2023
- 2023-06-13 JP JP2023097065A patent/JP7527049B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20221211T1 (hr) | Car-izražavajući vektor i t-stanice koje izražavaju car | |
JP2017513470A5 (hr) | ||
CL2021000479A1 (es) | Métodos de preparación de células que expresan receptores de antígenos quiméricos | |
FI2997141T3 (fi) | CD19-spesifinen kimeerinen antigeenireseptori ja sen käyttöjä | |
RU2021123419A (ru) | Химерные антигенные рецепторы и способы их получения | |
JP2022048153A5 (hr) | ||
HRP20201066T1 (hr) | Anti-pvrig antitijela i postupci uporabe | |
PH12019502411A1 (en) | Cells expressing chimeric activitaing receptors and chimeric stimulating receptors and uses thereof | |
HRP20201419T1 (hr) | Pripravci i postupci za imunoterapiju | |
FI3909972T3 (fi) | Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä | |
JP2018522564A5 (hr) | ||
WO2015172339A8 (zh) | 编码嵌合抗原受体蛋白的核酸及表达嵌合抗原受体蛋白的t淋巴细胞 | |
WO2017130223A3 (en) | A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof | |
EA201890294A1 (ru) | Химерный полипептидный комплекс и способы его получения и применения | |
MX2018004721A (es) | Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas. | |
MX2017003062A (es) | Receptores quimericos y usos de los mismos en terapia inmune. | |
RU2017102769A (ru) | EGFRvIII СПЕЦИФИЧЕСКИЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРЫ ДЛЯ ИММУНОТЕРАПИИ РАКА | |
MX2017001211A (es) | Receptores de antigenos quimericos ror1 (ntrkr1) especificos para inmunoterapia del cancer. | |
PE20241587A1 (es) | Receptores de antigenos quimericos que se dirigen a flt3 | |
RU2016143388A (ru) | Экспрессия трансгенов, регулируемая лекарственным средством | |
WO2017124001A3 (en) | T cell receptor-like antibodies specific for foxp3-derived peptides | |
WO2017066481A8 (en) | Chimeric antigen receptors containing a chlorotoxin domain | |
CL2022002327A1 (es) | Métodos de producción de células que expresan receptores antigénicos quiméricos | |
EP3806857A4 (en) | CD79B-BINDING CHEMERA ANTIGEN RECEPTORS | |
SA520412282B1 (ar) | خلية مؤهلة مناعيًا تعبر عن جزيء سطح خلية يتعرف على وجه التحديد على ccl19 il-7 ميزوثيلين بشري، |